Frontera Therapeutics
June 16, 2025
Company Presentation
Ophthalmology
Frontera is a global clinical-stage biotech company dedicated in developing innovative, high-quality, affordable rAAV gene therapies. Our work is backed by global top-notch scientists/KOLs and funded by the first-tier VC of ObiMed, Creacion, Sequoia, Boyu etc.
Our pipeline covers both prevalent and rare diseases in ophthalmology, hematology and cardiology. 4 ophthalmogy programs (nAMD, DME, XLRP, LCA2) have entered or completed Phase II trials, showing "Best-in-Class"potential compared to competitors.
Our R&D center in Boston has established a robust tech-platform for AAV capsids and payloads engineering and screening. We have developed propriatory AAV vectors that offer desired tissue tropism, durable gene expression with lower immunogenicity.
We're operating a state-of-the-art rAAV GMP manufacturing facility based on Sf9 BEVS production system in Suzhou. We've reached industry leading level of low empty capsid rate < 1% and significantly reduced the direct production cost by 90%.
Company HQ City:
Shanghai
Company HQ State:
Shanghai
Company HQ Country:
China
Year Founded:
2019
Lead Product in Development:
FT-003 is a clinical-stage anti-VEGF rAAV product to treat nAMD and DME through a sigle intravitreal injection. Through our propriatory vector optimization, FT-003 is developed with desired tissue tropism, durable transgene expression and low immunogenicity. FT-003 showed “Best-in-Class” potential with superior efficacy & safety in its early-stage clinical studies (>20 nAMD & DME patients followed up for 0.5-2 years). FT-003 is currently being evaluated in two clinical Phase 2 trials for nAMD and DME in China and received Phase 2 IND clearances from FDA for both indications in the U.S.
FT-002 is a clinical-stage rAAV product to treat XLRP patients through a single sub-retinal injection. The early clinical studies (>20 patients followed up for 0.5-1 year) showed "Best in Class"potential with significant improvements in retinal sensitivity and BCVA. FT-002 is currently evaluated in China Phase 2 trial and received Phase 2 IND clearance and ODD from FDA in the U.S.
CEO
Dr. Xinyan Li
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
FT-003: Phase 2 interium data readout (24 weeks post treatment)
FT-002: Phase 2 interium data readout (24 weeks post treatment)
What is your next catalyst (value inflection) update?
FT-003 Phase 2 interium data readout: October 2025
FT-002 Phase 2 interium data readout: December 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}